Maria Prins Selected Research

HIV Seropositivity

1/2019	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort.
1/2018	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.
10/2014	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study.
2/2012	Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-combination antiretroviral therapy era.
1/2012	Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia.
9/2008	Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.
9/2007	The HIV RNA setpoint theory revisited.
3/2006	Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.
9/2004	Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection.
12/2003	Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Prins Research Topics

Disease

68	Infections 01/2022 - 02/2002
21	Acquired Immunodeficiency Syndrome (AIDS) 12/2020 - 10/2002
20	Sexually Transmitted Diseases (Sexually Transmitted Disease) 05/2022 - 07/2007
18	HIV Infections (HIV Infection) 01/2021 - 03/2003
11	Hepatitis C 01/2022 - 10/2010
11	HIV Seropositivity 01/2019 - 10/2002
8	Disease Progression 01/2012 - 11/2004
7	Reinfection 01/2019 - 11/2011
5	Coinfection 01/2020 - 04/2013
5	Viremia 01/2017 - 03/2015
4	COVID-19 01/2022 - 01/2021
4	Hepatitis B 11/2021 - 01/2016
4	Hepatitis 06/2021 - 02/2008
4	Cognitive Dysfunction 08/2017 - 01/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 08/2009
3	Inflammation (Inflammations) 01/2017 - 12/2014
2	Fever (Fevers) 01/2019 - 11/2017
2	Frailty 01/2018 - 01/2016
2	Lymphogranuloma Venereum 11/2017 - 02/2008
2	Opportunistic Infections (Opportunistic Infection) 03/2016 - 03/2006
2	Neoplasms (Cancer) 01/2014 - 03/2005
2	Liver Diseases (Liver Disease) 04/2013 - 07/2010
2	Syphilis 07/2012 - 01/2012
1	Virus Diseases (Viral Diseases) 11/2021
1	Persistent Infection 01/2021
1	Chronic Hepatitis B 01/2020
1	Erectile Dysfunction 01/2020
1	Bronchitis 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Pharyngitis (Sore Throat) 01/2019
1	Human Influenza (Influenza) 01/2019
1	Urinary Tract Infections (Urinary Tract Infection) 11/2017
1	Fanconi Syndrome (Syndrome, Fanconi) 01/2017
1	Albuminuria 01/2017
1	Hypertension (High Blood Pressure) 01/2016
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2016
1	Jaundice (Icterus) 01/2016
1	Abdominal Obesity 01/2016
1	Osteoporosis 02/2015
1	Metabolic Bone Diseases (Osteopenia) 02/2015

Drug/Important Bio-Agent (IBA)

26	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2005
24	Pharmaceutical PreparationsIBA 01/2022 - 06/2002
10	VaccinesIBA 01/2022 - 10/2010
5	Antiviral Agents (Antivirals)IBA 10/2021 - 10/2015
4	Opioid Analgesics (Opioids)IBA 11/2021 - 01/2014
4	Biological ProductsIBA 01/2018 - 09/2003
4	Hepatitis C AntibodiesIBA 01/2016 - 03/2011
3	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2021 - 01/2018
2	Neutralizing AntibodiesIBA 01/2022 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2017
2	AntibodiesIBA 11/2021 - 01/2019
2	AntigensIBA 01/2021 - 08/2020
2	Indicators and Reagents (Reagents)IBA 11/2019 - 06/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 08/2010
2	EpitopesIBA 01/2019 - 01/2017
2	Immunoglobulin G (IgG)IBA 01/2019 - 01/2018
2	Antihypertensive Agents (Antihypertensives)IBA 01/2018 - 01/2016
2	Tenofovir (Viread)FDA Link 11/2017 - 01/2017
2	Broadly Neutralizing AntibodiesIBA 01/2017 - 01/2016
2	Interferon LambdaIBA 01/2016 - 11/2014
2	Heroin (Diamorphine)IBA 09/2014 - 08/2005
2	Methadone (Dolophine)FDA LinkGeneric 01/2014 - 09/2007
1	insulin receptor-related receptor (IRR)IBA 05/2022
1	BNT162 VaccineIBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	altersolanol AIBA 11/2021
1	ORALIT (ORS)IBA 11/2021
1	Anti-Idiotypic AntibodiesIBA 01/2021
1	HIV AntibodiesIBA 01/2021
1	NitritesIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	N 30IBA 01/2019
1	Alanine (L-Alanine)FDA Link 01/2019
1	Viral RNAIBA 01/2019
1	oxidized low density lipoproteinIBA 01/2019
1	LDL CholesterolIBA 01/2019
1	Antidepressive Agents (Antidepressants)IBA 01/2018
1	DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA 01/2018
1	Emtricitabine (Emtriva)FDA Link 11/2017
1	tenofovir diphosphateIBA 11/2017
1	CreatinineIBA 01/2017
1	Glycoproteins (Glycoprotein)IBA 01/2017
1	Phosphates (Orthophosphate)IBA 01/2017
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2017
1	Triglycerides (Triacylglycerol)IBA 01/2017
1	AlbuminsIBA 01/2017
1	Retinaldehyde (Retinal)IBA 03/2016
1	Didanosine (Videx)FDA LinkGeneric 01/2016
1	Transaminases (Aminotransferases)IBA 01/2016
1	NucleosidesIBA 01/2016
1	Stavudine (Zerit)FDA LinkGeneric 01/2016
1	Reverse Transcriptase InhibitorsIBA 01/2016
1	InterferonsIBA 10/2015
1	Ritonavir (Norvir)FDA Link 12/2014

Therapy/Procedure

29	Highly Active Antiretroviral Therapy (HAART) 01/2019 - 03/2003
23	Therapeutics 11/2021 - 10/2002
11	Condoms (Condom) 01/2021 - 05/2010
2	Tattooing 12/2016 - 01/2011
2	Enema (Enemas) 01/2012 - 02/2008
2	First Aid (Aids, First) 09/2008 - 10/2002